PACB vs. CRSP

Last updated Apr 2, 2026

Compare and contrast key facts about Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP).

Performance

PACB vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

PACB vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
PACB Pacific Biosciences of California, Inc.	-27.81%	2.19%	-81.35%	19.93%	-60.02%	-21.13%	404.67%	-30.54%	180.30%	-30.53%
CRSP CRISPR Therapeutics AG	-6.92%	33.23%	-37.12%	54.00%	-46.36%	-50.51%	151.39%	113.18%	21.68%	15.89%

Fundamentals

EPS PACB : -$1.82 CRSP : -$5.47
PS Ratio PACB : 2.54 CRSP : 118.44
Total Revenue (TTM) PACB : $160.01M CRSP : $36.75M
Gross Profit (TTM) PACB : $50.67M CRSP : -$130.60M
EBITDA (TTM) PACB : -$161.03M CRSP : -$529.50M

Returns By Period

In the year-to-date period, PACB achieves a -27.81% return, which is significantly lower than CRSP's -6.92% return.

PACB

• 1D: 2.27%
• 1M: -16.67%
• YTD: -27.81%
• 6M: -2.17%
• 1Y: 19.47%
• 3Y*: -51.15%
• 5Y*: -47.49%
• 10Y*: -17.60%

CRSP

• 1D: 2.61%
• 1M: -19.68%
• YTD: -6.92%
• 6M: -26.22%
• 1Y: 47.28%
• 3Y*: 2.57%
• 5Y*: -16.38%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PACB vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PACB

PACB Risk / Return Rank: 50
PACB Sharpe Ratio Rank: 48
PACB Sortino Ratio Rank: 56
PACB Omega Ratio Rank: 50
PACB Calmar Ratio Rank: 47
PACB Martin Ratio Rank: 47

CRSP

CRSP Risk / Return Rank: 64
CRSP Sharpe Ratio Rank: 66
CRSP Sortino Ratio Rank: 67
CRSP Omega Ratio Rank: 62
CRSP Calmar Ratio Rank: 63
CRSP Martin Ratio Rank: 60

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PACB vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PACB	CRSP	Difference
Sharpe ratio Return per unit of total volatility	0.21	0.75	-0.53
Sortino ratio Return per unit of downside risk	1.08	1.50	-0.42
Omega ratio Gain probability vs. loss probability	1.11	1.17	-0.06
Calmar ratio Return relative to maximum drawdown	0.27	1.03	-0.76
Martin ratio Return relative to average drawdown	0.57	2.03	-1.46
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PACB vs. CRSP - Sharpe Ratio Comparison

The current PACB Sharpe Ratio is 0.21, which is lower than the CRSP Sharpe Ratio of 0.75. The chart below compares the historical Sharpe Ratios of PACB and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PACB	CRSP	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.21	0.75	-0.53
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.51	-0.27	-0.23
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.21	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.18	0.22	-0.40

Correlation

The correlation between PACB and CRSP is 0.42, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

PACB vs. CRSP - Dividend Comparison

Neither PACB nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

PACB vs. CRSP - Drawdown Comparison

The maximum PACB drawdown since its inception was -98.22%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for PACB and CRSP.

Drawdown Indicators

	PACB	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-98.22%	-85.11%	-13.11%
Max Drawdown (1Y) Largest decline over 1 year	-52.81%	-42.25%	-10.56%
Max Drawdown (5Y) Largest decline over 5 years	-97.47%	-80.68%	-16.79%
Max Drawdown (10Y) Largest decline over 10 years	-98.22%	—	—
Current Drawdown Current decline from peak	-97.36%	-76.76%	-20.60%
Average Drawdown Average peak-to-trough decline	-70.20%	-48.71%	-21.49%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.13%	21.35%	+3.78%

Volatility

PACB vs. CRSP - Volatility Comparison

Pacific Biosciences of California, Inc. (PACB) and CRISPR Therapeutics AG (CRSP) have volatilities of 18.87% and 18.14%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PACB	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.87%	18.14%	+0.73%
Volatility (6M) Calculated over the trailing 6-month period	66.55%	44.91%	+21.64%
Volatility (1Y) Calculated over the trailing 1-year period	91.93%	63.81%	+28.12%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.92%	60.36%	+33.56%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	84.46%	64.42%	+20.04%

Financials